Skip to main
CODX

Co-Diagnostics (CODX) Stock Forecast & Price Target

Co-Diagnostics (CODX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Co-Diagnostics Inc. is positioned positively within the expanding market for respiratory infectious disease diagnostics, particularly in the Middle East, driven by significant investments in the Kingdom of Saudi Arabia. The establishment of a joint venture with Arabian Eagle Manufacturing to commercialize Co-Dx technologies across the region signals strategic growth opportunities, although immediate financial impacts may be limited. Additionally, the company's development of proprietary instruments for its Co-Dx PCR platform enhances its offerings and may lead to improved operational efficiency and potential market differentiation moving forward.

Bears say

Co-Diagnostics Inc faces significant risks that could hinder its financial performance and overall viability, including potential failures in clinical evaluations, regulatory clearance, and commercial success against competition, all leading to potential dilution issues for shareholders. In the third quarter of 2025, the company reported a modest revenue of $145,000 while incurring a substantial net loss of $5.9 million, equating to a loss of $0.16 per share. These financial metrics, coupled with concerns about future fundraising becoming more dilutive and less favorable, contribute to a negative outlook for Co-Diagnostics's stock.

Co-Diagnostics (CODX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Co-Diagnostics (CODX) Forecast

Analysts have given Co-Diagnostics (CODX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Co-Diagnostics (CODX) has a Strong Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Co-Diagnostics (CODX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.